Prothena reported $3.35M in Interest Income for its fiscal quarter ending in September of 2025.





Interest Income Change Date
Acadia Pharmaceuticals USD 7.24M 658K Jun/2025
Agios Pharmaceuticals USD 13.37M 1.14M Sep/2025
ALKERMES USD 11.94M 853K Sep/2025
Alnylam Pharmaceuticals USD 28.68M 1.19M Sep/2025
Biogen USD 31.6M 700K Sep/2025
BioMarin Pharmaceutical USD 17.85M 973K Sep/2025
Exelixis USD 15.92M 867K Sep/2025
Immunic USD -0.24 0.03 Sep/2024
Incyte USD 30.75M 3.97M Dec/2025
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
MacroGenics USD 1.53M 114K Sep/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Prothena USD 3.35M 443K Sep/2025
Regeneron Pharmaceuticals USD 175.1M 300K Sep/2025
Ultragenyx Pharmaceutical USD 5.86M 69K Sep/2025
Vertex Pharmaceuticals USD 125.7M 3.3M Sep/2025